
Post hoc exploratory analysis of rucaparib in patients with platinum-sensitive recurrent ovarian carcinoma from the randomized, placebo-controlled phase III study ARIEL3: Effect of a deleterious germline or no germline mutation on efficacy
Coleman, R.L., Oza, A.M., Lorusso, D., Aghajanian, C.A., Oaknin, A., Dean, A., Colombo, N., Weberpals, J.I., Clamp, A.R., Scambia, G., Leary, A., Holloway, R.W., Gancedo, M. Amenedo, Fong, P.C.C., GohVolume:
154
Langue:
english
Journal:
Gynecologic Oncology
DOI:
10.1016/j.ygyno.2019.04.549
Date:
June, 2019
Fichier:
PDF, 242 KB
english, 2019